Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
ODDITY TECH 0CDI.PA-O 0META 11.03MNT.TO 0.69COPX 1.79U.U.TO 0.5SII.TO 2.94IPCO.TO -0.43
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.57
+0.60 (2.15%)
as of Aug 25, 2026, 8:00:00 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) has faced challenges following its prominent role during the Covid-19 pandemic, with many experts pointing out the looming patent cliffs and the need for new blockbuster drugs to sustain growth. The company is heavily reliant on its dividends, offering yields between 6% to 8%, which many investors find attractive in a low growth environment. While some view it as a value play due to its low price-to-earnings ratio, others express concerns that it may be a value trap due to uncertain growth prospects. The overall sentiment reflects a cautious approach, favoring the dividend payout amidst worries about drug pipeline sustainability and the impact of recent acquisitions on its future performance.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
COMMENT

Pfizer Inc(PFE)

Aug 21, 2012

Like other entities in the big Pharma space it is going to be really challenged from a growth perspective in the next little while. In general, no one should be over enthusiastic about the pipeline of new drugs at this stage. Because of their size, it is very difficult for them to grow. Governments are very constrained on what they are allowed to spend on healthcare.

Photo of Karl BergerKarl BergerUnlock Rating
$23.69

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 09, 2012

Looks for minimum 5% sale growth and you are not getting that in any o the big pharmas. A good company and very stable. Value with some yield there is nothing wrong with it but he would not buy it. 3.7% dividend.

Photo of Mark GrammerMark Grammer
No
Unlock Rating
$23.87

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 09, 2012

Likes this stock. Pays a nice 3.7% dividend. You are not buying this necessarily for strong earnings per share growth long-term. You are buying it for cash flow and dividend yield. Growth rate of the dividend yield should be around 8.5% per year projected over the next 3 years.

Photo of Stan WongStan Wong
Owned
Unlock Rating
$23.87

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 31, 2012

All the drugs are moving. We are finally in a good space for them. Model of $28.28. 19% upside.

Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$24.04

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 26, 2012
Base pharmaceutical company and have an AA rating. Chart shows a long upward trend. 3.75% dividend yield. Stop loss would be about $20.25. Target price of $31.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
Owned
Unlock Rating
$23.49

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jul 25, 2012
(Market Call Minute.) A cash cow. Not a lot of growth here but a good yield.
Photo of Gordon ReidGordon ReidUnlock Rating
$23.33

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 20, 2012
Like many of the pharmaceutical companies, it has been a very slow grower. Structurally, with US legislature, it is difficult to fund drugs that are going to be successful that would generate a cash flow that will pay back the company before they go generic. Feels that this company gives you a good return but you are stuck with the low single digit growth. Better opportunities elsewhere.
Photo of Gordon ReidGordon ReidUnlock Rating
$22.67

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 20, 2012
Will be issuing an IPO on their pet medicine branch. This is the right step to downsize a little. A mammoth company that is having difficulty in getting all the pieces growing at the same time. Sold their nutrition business. Very low multiple and a nice yield but just not enough growth.
Photo of Don LatoDon Lato
No
Unlock Rating
$22.67

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jun 14, 2012
Model price $26.71, 21% upside. This market is looking for yield, which is 3.9% here. A perfect candidate if you want to hide in equities. Likes this space also.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.56

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jun 07, 2012
Generally, healthcare sector tends to be more defensive and stable. Nice yield of about 4%. Also expects there are some catalysts around the areas that this company might change or spin off, which could enhance shareholder value
Photo of Stan WongStan Wong
Owned
Unlock Rating
$21.94

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 18, 2012
We are in an environment where dividends count. This one gives a 3% plus yield. Any time the market goes through deflationary pockets, money rotates back to consumer staples, drugs, etc.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.57

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 20, 2012
Thinks there is lots of potential. Drug stocks are severely under owned. The patent cliff that people were looking for has already happened and they are looking forward to the new drugs that are coming along. The CEO decided PFE was too big so any big drug coming along would have to be mammoth to have an impact, so he is actively talking about selling off some parts of the business, such as the Animal health. Nice yield. Earnings start to grow after next year or two.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.80

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 13, 2012
Prefers Teva to Pfizer. PFE does not have the growth profile. 11 or 12 times earnings. Abbot labs are good too. If it falls 10% he would be all over it.
Photo of Barry SchwartzBarry Schwartz
No
Unlock Rating
$22.01

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 13, 2012
(A Top Pick Feb 28/11. Up 13.97%.)
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$21.30

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 02, 2012
Dividend is safe, growth prospects of many of the large Parma are very muted.
Photo of Don LatoDon LatoUnlock Rating
$21.11

Stock price when the opinion was issued

$28.57

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 406 to 420 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

ATD.TO -0.8$85.19
1523.HK 0$
CSU.TO -20.01$3078.66
NVO 1.74$48.66
PAYC 2.08$231.7

Today's Top Picks

ODDITY T… 0$
CDI.PA-O 0$
META 11.03$570.05
MNT.TO 0.69$69.95
COPX 1.79$96.32

Popular Articles

Latest Sell Signals

ORCL 2.31$144.76
GAW-LSE 0$
BB.TO 0.17$10.79
SHOP.TO 5.21$212.84
IBM 3.15$234.19

Most Recent Experts

Jason Del Vicario

Jason Del Vicario

HollisWealth

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like